27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Postoperative cognitive dysfunction (POCD) is a common disorder following surgery, which seriously threatens the quality of patients' life, especially the older people. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) is a heterogeneous disorder with multiple etiologies. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB) are clinically and neuropathologically highly related α-synucleinopathies that collectively constitute the second leading cause of neurodegenerative dementias. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Thalamic atrophy is a common feature across all forms of FTD but little is known about specific nuclei involvement. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
The aging population is expanding, as is the prevalence of age-related cognitive decline (ARCD). 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source
Assistive technology (AT) involvement in therapeutic treatment has provided simple and efficient healthcare solutions to people. 5 key findings →
Participants: 38 Evidence: low
Full summary, score breakdown and related studies → Original source
Diabetes is becoming one of the most widespread health burning problems in the elderly. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
A total of 41 articles met the eligibility criteria. 5 key findings →
Participants: 41 Evidence: low
Full summary, score breakdown and related studies → Original source
Educational programs may be useful in reducing racial differences in attitudes towards ACP. 2 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Of the 15 articles that were included, most used qualitative methods (N = 13) and were conducted in long-term care facilities (N = 14). 1 key finding →
Participants: 13 Evidence: low
Full summary, score breakdown and related studies → Original source
A gap of knowledge, of information and in care intertwiningly hinder advance care planning. 2 key findings →
Participants: 15 Evidence: low
Full summary, score breakdown and related studies → Original source
Experiences translated into four themes: acknowledging human dignity; being recognised as an important caregiver; (not) talking about death and dying and making decisions together. 5 key findings →
Participants: 32 Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia is a devastating disease and global health challenge that is highly prevalent worldwide. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Cerebral small vessel disease (cSVD) comprises pathological processes of the small vessels in the brain that may manifest clinically as stroke, cognitive impairment, dementia, or gait disturbance. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Drug development continues robustly at all phases despite setbacks in several programs in the recent past. 2 key findings →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source
Familial Alzheimer's disease (fAD) mutations alter amyloid precursor protein (APP) cleavage by γ-secretase, increasing the proportion of longer amyloidogenic amyloid-β (Aβ) peptides. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Plasma Aβ measures may be useful biomarkers for predicting cerebral Aβ and tau. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Circulating long noncoding RNAs (lncRNAs) might serve as biomarkers for different pathological conditions. 5 key findings →
Participants: 45 Evidence: low
Full summary, score breakdown and related studies → Original source
Plasma Aβ ratios in this study are a potential biomarker for brain Aβ deposition and therefore, for preclinical AD. 2 key findings →
Participants: 32 Evidence: low
Full summary, score breakdown and related studies → Original source
The primary Aβ-based blood biomarker funnels individuals with suspected AD for subsequent validation of the diagnosis by structure-based combined analysis of the CSF biomarkers Aβ and tau. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We use a genome-wide association of 1 million parental lifespans of genotyped subjects and data on mortality risk factors to validate previously unreplicated findings near CDKN2B-AS1 , ATXN2/BRAP , FURIN/FES , ZW10 , PSORS1C3 , and 13q21.31, and identify and replicate novel findings near ABO , ZC3HC1 , and IGF2R . 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Neuroinflammation and microglial activation are significant processes in Alzheimer's disease pathology. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Genome-wide association studies (GWAS) originally identified ATP-binding cassette, sub-family A, member 7 (ABCA7), as a novel risk gene of Alzheimer's disease (AD). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The accumulation of pathological misfolded tau is a feature common to a collective of neurodegenerative disorders known as tauopathies, of which Alzheimer's disease (AD) is the most common. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Tauopathies are neurodegenerative diseases characterized by aberrant forms of tau protein accumulation leading to neuronal death in focal brain areas. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →